Outlook Therapeutics Files 10-Q for Q2 2025

Ticker: OTLK · Form: 10-Q · Filed: May 15, 2025 · CIK: 1649989

Outlook Therapeutics, Inc. 10-Q Filing Summary
FieldDetail
CompanyOutlook Therapeutics, Inc. (OTLK)
Form Type10-Q
Filed DateMay 15, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, biotech

TL;DR

OTLK 10-Q filed. Financials for Q2 2025 out.

AI Summary

Outlook Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Oncobiologics, Inc., reported financial data for its fiscal second quarter. Key financial metrics and operational details are presented in this filing, which was submitted on May 15, 2025.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for Outlook Therapeutics, crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Outlook Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

  • 23,905,635 — Total Assets (Reported for the period ending March 31, 2025)
  • 32,907,014 — Total Liabilities (Reported for the period ending March 31, 2025)

Key Players & Entities

  • Outlook Therapeutics, Inc. (company) — Filer of the 10-Q
  • Oncobiologics, Inc. (company) — Former name of Outlook Therapeutics
  • March 31, 2025 (date) — End of reporting period
  • May 15, 2025 (date) — Filing date

FAQ

What were Outlook Therapeutics' total assets as of March 31, 2025?

Outlook Therapeutics' total assets were $23,905,635 as of March 31, 2025.

What were Outlook Therapeutics' total liabilities as of March 31, 2025?

Outlook Therapeutics' total liabilities were $32,907,014 as of March 31, 2025.

When was the 10-Q filing for Outlook Therapeutics submitted?

The 10-Q filing was submitted on May 15, 2025.

What is the fiscal year end for Outlook Therapeutics?

The fiscal year end for Outlook Therapeutics is September 30.

What was the former name of Outlook Therapeutics?

The former name of Outlook Therapeutics was Oncobiologics, Inc.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Outlook Therapeutics, Inc. (OTLK).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.